难治性胃食管反流病的药物治疗研究进展  

Advances in Drug Treatment of Refractory Gastroesophageal Reflux Disease

作　　者：李东阳 杨朝霞[2] 

机构地区：[1]重庆医科大学第二临床学院,重庆 [2]重庆医科大学附属第二医院消化内科,重庆

出　　处：《临床医学进展》2024年第5期645-653,共9页Advances in Clinical Medicine

摘　　要：胃食管反流病(GERD)是一种由胃、十二指肠内容物反流引起的常见的消化系统疾病,常见症状有反酸、烧心、胸痛、嗳气和吞咽困难。GERD发病率在世界范围内很高(2.5%~51.2%)。在大多数情况下,质子泵抑制剂(PPI)可有效治愈病变和改善症状,但高达30%的GERD患者对PPI治疗反应不足。中国专家共识将经双倍标准剂量抑酸剂治疗8周后,反流、烧心等症状仍无明显改善的GERD定义为难治性胃食管反流病(RGERD)。RGERD严重影响患者生活质量,也会增加医疗保健资源的消耗。本文就近年来RGERD药物治疗的研究进展作一综述。Gastroesophageal reflux disease (GERD) is a common digestive system disease caused by reflux of stomach and duodenal contents, with common symptoms including acid reflux, heartburn, chest pain, belching and dysphagia. The incidence of GERD is high worldwide (2.5%~51.2%). In most cases, proton pump inhibitors (PPIs) are effective in curing lesions and improving symptoms, but up to 30% of GERD patients do not respond adequately to PPI treatment. Chinese experts agree that GERD with no significant improvement in reflux, heartburn and other symptoms after 8 weeks of treatment with double standard dose of acid suppressants is defined as refractory gastroesophageal reflux disease (RGERD). RGERD seriously affects the quality of life of patients and also increases the consumption of healthcare resources. This article reviews the recent progress in drug therapy of RGERD.

关 键 词：难治性胃食管反流病 药物治疗 研究进展 

分 类 号：R57[医药卫生—消化系统]